Advertisement

A Non-Interventional Retrospective Evaluation of Resources Consumed During the Provision of Care for Overactive Bladder Syndrome: A Real World Evaluation: German Perspective (The Reduce Study)

      Objectives

      To evaluate resource utilisation for subjects with overactive bladder (OAB) syndrome who are managed with the commonly prescribed oral medications: solifenacin succinate, tolterodine tartrate, or trospium chloride from the payer perspective.

      Methods

      Data were abstracted from medical records for qualified subjects who were ≥ 18 years, with a diagnosis for OAB (at least one of the following: urgency, frequency with or without urgency incontinence) on or before December 31, 2010. Subjects must have been on one of the study medications for at least 3 months and have at least 12 months of medical records available. The study was approved by local ethics committees and all data provided was anonymised. Medication costs for Germany are reported for 2013 €.

      Results

      A total of 136 of 229 subjects were included for the German analysis. The remaining subjects were from the Czech Republic to be reported elsewhere. Top 3 reasons for exclusion from Germany include: primary diagnosis of urinary tract infection, urologic surgery within 6 months of the data collection, and diabetic neuropathy. The annual overall mean cost for office visits, specialist visits, investigations, other treatments, medications and incontinence pad use with solifenacin (5,10mg/day) (N=60), trospium (IR and ER maximum dose of 60mg/day) (N=51), and tolterodine (IR 2, 4mg/day and ER 4mg/day) (N=25), were €1,059.31, €1,247.76, and €1,626.01, respectively. Incontinence pad use for weekly frequency with solifenacin, trospium, and tolterodine was, 17.34, 19.51 and 20.35, respectively. Overall satisfaction with medication as perceived by the clinician (very satisfied, satisfied, neutral, dissatisfied, very dissatisfied) for very satisfied and satisfied was 97%, 86%, 100%, for solifenacin, trospium, tolterodine, respectively.

      Conclusions

      Solifenacin had the lowest annual cost-in-use compared to other study drug annual cost. This was corroborated in part by the lowest incontinence pad use for solifenacin compared to trospium and tolterodine and the high treatment satisfaction.